Affitech appoints cfo

Stig Jarle Pettersen was formerly a consultant to the Danish antibody medicines firm

Affitech, a Danish antibody medicines company, has appointed Stig Jarle Pettersen as chief financial officer.

Pettersen will be a member of the executive management of Affitech with managing director Martin Welschof and chief scientific officer Alexander Duncan.

Pettersen is a Norwegian state authorised public accountant with more than 20 years of experience at Hafslund Nycomed, Helicopter Services Group, Alpharma, Actavis and most recently as chief financial officer at Xellia Pharmaceuticals.

Pettersen worked as a consultant for Affitech in September 2009 and participated in the process of restructuring and refinancing the company. He now joins the company when, due to investment by TransNova in April, it is able to finance the further development of its two leading drug candidates in collaboration with NTSPlus of Russia.

Affitech expects to file a Clinical Trial Application in 2011 for its anti-VEGF antibody AT001/r84, whose main indication is for anti-angiogenesis treatment in several cancers.

You may also like

Regulatory

TurboFil debuts latest generation of through-the-tip benchtop syringe filler

TipFil Plus provides precise, aseptic-ready filling and capping for lab and pharmacy applications
Manufacturing

Concentrating recombinant proteins for drug discovery using centrifugal evaporation

Exploring purification, concentration and sample protection in recombinant protein workflows
Research & Development

COVID-19 immunity lowers the risk of a new pandemic

Researchers at the MRC-University of Glasgow Centre for Virus Research have demonstrated that the likelihood of the emergence of a new SARS-type virus pandemic has been significantly reduced by population-wide immunity to SARS-CoV-2
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Cytiva enters research partnership with SRTIGET for next-gen genomic medicine

The pair aim to expand the role of lipid nanoparticle technology into gene therapy delivery, including applications in cancer and inherited blood diseases, CNS delivery for neurological disorders where current methods fail and in vivo stem cell modification that could eliminate toxic conditioning regimens
Research & Development

Shimadzu’s Design Craftech

Fusing traditional Kyoto craft techniques with industrial production
Research & Development

Just – Evotec Biologics wins BARDA contract to optimise antibody biomanufacturing against Ebola and Sudan virus

Just – Evotec Biologics has been selected by BARDA to develop scalable, high-yield manufacturing processes for a monoclonal antibody cocktail targeting filovirus diseases under a multi-year programme valued at up to $10m
Ingredients

dsm-firmenich launches ModulaSENSE Bitter to tackle bitterness in oral drug formulations

The new taste modulation technology combines bitter blockers, maskers and sweeteners with receptor-based analysis to help pharmaceutical formulators improve the palatability of oral medicines
Subscribe now